声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 点击查看公告原文>> 责任编辑：小浪快报 9月25日10:00 - 11:00，华东医药在公司会议室接待了来自花旗银行、Carlyle、Sumitomo Mitsui DS Asset Management等15家机构的15位投资者，进行了现场调研。公司首席科学官刘东舟、董事会秘书陈波参 与接待。 公司经营情况概述 华东医药成立于1993年，1999年在深交所上市，业务覆盖医药全产业链，拥有医药工业、医药商业、医 美、工业微生物四大业务板块。2025年上半年，公司实现营业收入216.75亿元，归属于上市公司股东的 净利润18.15亿元。公司连续十六年登上《财富》中国500强，入选美国《制药经理人》全 ...

证券代码：000963 证券简称：华东医药 华东医药股份有限公司投资者关系活动记录表 编号：2025-006 | 投资者关系 | □特定对象调研 □分析师会议 □媒体采访 | | | --- | --- | --- | | | □业绩说明会 | | | 活动类别 | □新闻发布会 □路演活动 | | | | □现场参观 ☑其他 现场调研 | | | 参与单位名 | 参与单位：花旗银行、Carlyle、Sumitomo Mitsui DS Asset Management、 、 | | | | American Century Investment Management Macquarie Investment | | | 称及人员姓 | Management 、 Federated Hermes 、 Point72 Asset Management | 、 | | 名 | Handelsbanken Fonder、Polar Capital、Kieger、3W Fund Management | 等 | | | 机构投资者 15 人。 | | | 时间 | 年 月 日 2025 9 25 10:00-11:0 ...

Core Viewpoint - Huadong Medicine reported steady growth in its financial performance for the first half of 2025, driven by the successful launch of innovative products and a strategic shift from traditional generic drugs to innovative pharmaceuticals [1][2]. Financial Performance - The company achieved total revenue of 21.675 billion yuan, a year-on-year increase of 3.39% [1]. - The net profit attributable to shareholders reached 1.815 billion yuan, up 7.01% year-on-year, while the net profit after deducting non-recurring gains and losses was 1.762 billion yuan, reflecting an 8.40% increase [1]. - The core subsidiary, China-U.S. Huadong, reported revenue of 7.317 billion yuan, a 9.24% increase, and a net profit of 1.580 billion yuan, up 14.09% [5]. Innovative Product Growth - Sales and agency service revenue from innovative products reached 1.084 billion yuan, with a significant year-on-year growth of 59% [1]. - The CAR-T product, Zekai Ze® (注射液), has completed certifications in over 20 provinces and has received more than 111 valid orders, with over 100 insurance projects covering it [5][6]. - The company is also commercializing PARP inhibitor, Senapali capsules (派舒宁®), and has established a presence in over 600 medical institutions [6]. Market Dynamics and Competition - The competitive landscape is intensifying, with multinational pharmaceutical companies accelerating localization in China and domestic biotech firms potentially shortening Huadong's first-mover advantage [2]. - The company needs to continue investing in R&D and strengthen its commercialization network to address price wars and market share competition [2]. Research and Development Focus - Huadong Medicine is focusing on ADC and GLP-1 as its main research directions, with several ADC drugs in advanced clinical trials [8][9]. - The company has received orphan drug designation for its ADC drug HDM2005 and has initiated clinical trials for multiple innovative drugs targeting various diseases [8][9]. Future Outlook - Analysts predict that GLP-1 products will become the largest drug category globally in the next 3 to 5 years, although recent market expectations have been adjusted downward [10]. - The company's short-term stability is expected to remain strong, but its long-term competitiveness will depend on its ability to launch successful products in oncology and metabolic diseases [10].

Core Viewpoint - Huadong Medicine reported a steady growth in its performance for the first half of 2025, with revenue and net profit showing positive year-on-year increases, indicating a robust operational trend and commitment to shareholder returns through dividends [1] Financial Performance - In the first half of 2025, Huadong Medicine achieved total revenue of 21.675 billion yuan, a year-on-year increase of 3.39% [1] - The company reported a net profit attributable to shareholders of 1.815 billion yuan, up 7.01% year-on-year, and a net profit excluding non-recurring items of 1.762 billion yuan, reflecting an 8.40% increase [1] - A mid-year dividend of 614 million yuan is proposed, representing 33.83% of the net profit for the first half of 2025 [1] Business Segments - The core subsidiary, Zhongmei Huadong, maintained a strong growth trend with revenue of 7.317 billion yuan, a 9.24% increase year-on-year, and a net profit of 1.580 billion yuan, up 14.09% [2] - The second quarter alone saw revenue of 3.696 billion yuan, a 12.04% increase, and a net profit of 737 million yuan, reflecting a 16.34% growth [2] - Innovative product sales and agency services generated 1.084 billion yuan, marking a significant 59% year-on-year increase [2] Product Development and Innovation - The company is advancing its research and development efforts, with a 33.75% increase in R&D investment to 1.484 billion yuan in the first half of 2025 [4] - Direct R&D spending reached 1.174 billion yuan, a 54.21% increase, accounting for 15.97% of the pharmaceutical industrial revenue [4] - Huadong Medicine is developing over 80 innovative drug pipelines across three core therapeutic areas: oncology, endocrinology, and autoimmune diseases [4] Strategic Collaborations and Market Expansion - The CAR-T product, Zekai Ze (注射液), has received positive clinical feedback and is expanding its market coverage, with over 20 provinces certified for medical institution use [2] - The collaboration with Quanxin Biotech on the drug Seluxin has seen over 1,200 hospitals prescribing it since its approval in November 2024 [3] Industrial and Commercial Growth - The pharmaceutical commercial segment achieved revenue of 13.947 billion yuan, a 2.91% increase, with a net profit of 226 million yuan, up 3.67% [7] - The industrial microbiology segment reported sales of 368 million yuan, a 29% increase year-on-year, focusing on xRNA raw materials and other core business areas [7] - The aesthetic medicine sector has established a comprehensive high-end product line, with 40 international products, 26 of which are already on the market [7]

Core Viewpoint - Huadong Medicine reported a steady growth in its financial performance for the first half of 2025, with revenue reaching 21.675 billion yuan, a year-on-year increase of 3.39%, and a net profit of 1.815 billion yuan, up 7.01% [1] Financial Performance - The company achieved a total revenue of 21.675 billion yuan in the first half of 2025, reflecting a 3.39% increase year-on-year [1] - The net profit attributable to shareholders was 1.815 billion yuan, marking a 7.01% growth, while the net profit excluding non-recurring items was 1.762 billion yuan, up 8.40% [1] - A mid-year dividend of 614 million yuan is proposed, representing 33.83% of the net profit for the first half of 2025 [1] Business Growth and Product Commercialization - Huadong Medicine's core subsidiary, Zhongmei Huadong, reported a revenue of 7.317 billion yuan, a 9.24% increase, and a net profit of 1.580 billion yuan, up 14.09% [2] - The innovative product sales and agency service revenue reached 1.084 billion yuan, with a significant growth of 59% [2] - The CAR-T product, Zekai Ze, has expanded its market coverage, with over 20 provinces certified and more than 100 insurance projects included for reimbursement [2] R&D and Innovation - The company invested 1.484 billion yuan in R&D, a 33.75% increase, with direct R&D spending at 1.174 billion yuan, up 54.21% [6] - Huadong Medicine is advancing over 80 innovative drug pipelines, focusing on oncology, endocrinology, and autoimmune diseases [6][7] - The ADC product pipeline is progressing well, with several candidates in clinical trials and receiving orphan drug designation from the FDA [8] Industrial Microbiology and Aesthetic Medicine - The industrial microbiology segment achieved sales of 368 million yuan, a 29% increase, with significant growth in various sub-segments [10] - The aesthetic medicine division has launched multiple products, with strong market reception and ongoing registration efforts for new products [11][12] - The company aims to enhance its global presence and continue driving innovation in both pharmaceutical and aesthetic sectors [12]